Literature DB >> 27583025

Ultrasound-guided radiofrequency ablation for cT1a renal masses in poor surgical candidates: mid-term, single-center outcomes.

Ioannis Zachos1, Konstantinos Dimitropoulos2, Anastasios Karatzas1, Michael Samarinas1, Argiro Petsiti3, Vassilios Tassoudis3, Vassilios Tzortzis1.   

Abstract

OBJECTIVES: Surgical management of small renal masses can be challenging in frail patients and thus modalities such as radiofrequency ablation (RFA) have emerged as valid alternative options. The aim of the current study was to present mid-term oncological and functional results on a series of patients with cT1a renal cell carcinomas (RCCs) who were unfit for surgery and underwent RFA using ultrasound guidance under local anesthesia.
METHODS: Data from patients fulfilling the study selection criteria were retrospectively collected. RENAL nephrometry score was used for tumor description. Parametric tests were used for data analysis and survival curves were estimated using the Kaplan-Meier method.
RESULTS: Overall, 32 patients (mean±standard deviation age, 72.4 ± 7.6 years) with biopsy-proven RCCs (tumor size, 23.75 ± 10.44 mm and RENAL score, 5.28 ± 1.33) underwent 32 RFA sessions. Twenty-seven patients (84.4%) had low complexity masses and five patients had masses of intermediate complexity (15.6%) according to RENAL score categorization. Over a follow-up period of 22.1 ± 13.7 months, one case of primary treatment failure was recognized (primary technical success 97.0%), and overall, three patients were diagnosed with residual disease (primary technique effectiveness 90.6%). No major complications occurred during the postprocedure 90-day follow up, while no difference was found in serum creatinine and estimated glomerular filtration rate pre and post procedure. Patients with intermediate-complexity renal lesions had shorter time to recurrence in comparison to low-complexity masses (p = 0.002). All patients were alive at the time of study data analysis without diagnosed metastases.
CONCLUSIONS: Percutaneous RFA of small RCCs using ultrasound-based guidance under local anesthesia can be an effective alternative method for managing patients who are unfit for surgery.

Entities:  

Keywords:  frail; radiofrequency ablation; renal cancer; small renal masses; ultrasound; unfit

Year:  2016        PMID: 27583025      PMCID: PMC4981291          DOI: 10.1177/1758834016654694

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN: 1758-8340            Impact factor:   8.168


  33 in total

Review 1.  Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis.

Authors:  Alessandro Conti; Matteo Santoni; Valeria Sotte; Luciano Burattini; Marina Scarpelli; Liang Cheng; Antonio Lopez-Beltran; Rodolfo Montironi; Stefano Cascinu; Giovanni Muzzonigro; Lars Lund
Journal:  Urol Oncol       Date:  2015-05-13       Impact factor: 3.498

2.  Percutaneous radio frequency ablation of renal masses: results at a 2-year mean followup.

Authors:  Ioannis M Varkarakis; Mohamad E Allaf; Takeshi Inagaki; Sam B Bhayani; David Y Chan; Li-Ming Su; Thomas W Jarrett; Louis R Kavoussi; Stephen B Solomon
Journal:  J Urol       Date:  2005-08       Impact factor: 7.450

3.  Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update.

Authors:  Muneeb Ahmed; Luigi Solbiati; Christopher L Brace; David J Breen; Matthew R Callstrom; J William Charboneau; Min-Hua Chen; Byung Ihn Choi; Thierry de Baère; Gerald D Dodd; Damian E Dupuy; Debra A Gervais; David Gianfelice; Alice R Gillams; Fred T Lee; Edward Leen; Riccardo Lencioni; Peter J Littrup; Tito Livraghi; David S Lu; John P McGahan; Maria Franca Meloni; Boris Nikolic; Philippe L Pereira; Ping Liang; Hyunchul Rhim; Steven C Rose; Riad Salem; Constantinos T Sofocleous; Stephen B Solomon; Michael C Soulen; Masatoshi Tanaka; Thomas J Vogl; Bradford J Wood; S Nahum Goldberg
Journal:  J Vasc Interv Radiol       Date:  2014-10-23       Impact factor: 3.464

4.  The performance of a modified RENAL nephrometry score in predicting renal mass radiofrequency ablation success.

Authors:  Jeffrey C Gahan; Michael D Richter; Casey A Seideman; Clayton Trimmer; Danny Chan; Matthew Weaver; Ephrem O Olweny; Jeffrey A Cadeddu
Journal:  Urology       Date:  2014-10-18       Impact factor: 2.649

Review 5.  Increased incidence of serendipitously discovered renal cell carcinoma.

Authors:  M Jayson; H Sanders
Journal:  Urology       Date:  1998-02       Impact factor: 2.649

6.  Feasibility of percutaneous nephrolithotomy under assisted local anaesthesia: a prospective study on selected patients with upper urinary tract obstruction.

Authors:  Evangelos Aravantinos; Anastasios Karatzas; Stavros Gravas; Vassilios Tzortzis; Michael Melekos
Journal:  Eur Urol       Date:  2006-06-30       Impact factor: 20.096

7.  Treatment management of small renal masses in the 21st century: a paradigm shift.

Authors:  Maxine Sun; Firas Abdollah; Marco Bianchi; Quoc-Dien Trinh; Claudio Jeldres; Rodolphe Thuret; Zhe Tian; Shahrokh F Shariat; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz
Journal:  Ann Surg Oncol       Date:  2012-02-10       Impact factor: 5.344

8.  Midterm results of radiofrequency ablation versus nephrectomy for T1a renal cell carcinoma.

Authors:  Haruyuki Takaki; Koichiro Yamakado; Norihito Soga; Kiminobu Arima; Atsuhiro Nakatsuka; Masataka Kashima; Junji Uraki; Tomomi Yamada; Kan Takeda; Yoshiki Sugimura
Journal:  Jpn J Radiol       Date:  2010-07-27       Impact factor: 2.374

9.  Renal cell carcinoma in patients with a solitary kidney after nephrectomy treated with radiofrequency ablation: mid term results.

Authors:  Ralf-Thorsten Hoffmann; Tobias F Jakobs; Constanze H Kubisch; Christoph Trumm; Christof Weber; Michael Siebels; Thomas K Helmberger; Maximilian F Reiser
Journal:  Eur J Radiol       Date:  2009-01-31       Impact factor: 3.528

10.  Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses.

Authors:  R Houston Thompson; Tom Atwell; Grant Schmit; Christine M Lohse; A Nicholas Kurup; Adam Weisbrod; Sarah P Psutka; Suzanne B Stewart; Matthew R Callstrom; John C Cheville; Stephen A Boorjian; Bradley C Leibovich
Journal:  Eur Urol       Date:  2014-08-06       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.